Nature Biotechnology's Melanie Senior writes that private biotech financing in 2023 is more discriminate, disciplined and demanding, and that strong data and efficiency are derigueur. Forbion's Managing Partner Sander Slootweg delivers his take on what is in store for the industry. Click here to access the article online.